CCRL2 silencing suppresses MDS/sAML cell growth and sensitizes them to hypomethylating agents but does not affect the survival and clonogenicity of healthy CD34 + cells(14, 15). The gene discussed is CCRL2; the disease is myelodysplastic syndrome.